Cyclin-dependent kinase 4 (CDK4) inhibitors are introduced as novel drugs by targeting and disrupting the CDK4-related cell cycle progression of cancer cells in recent years (Goel et al., 2018; Deng et al., 2018). Here, CDK4 is linked to cancer.